Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery (RAAPID-II)

This study has been completed.
Sponsor:
Collaborator:
Kaneka Pharma America LLC
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01404910
First received: July 26, 2011
Last updated: September 25, 2015
Last verified: September 2015